Biggest News Aggregation in the World
📰 Noah Berkowitz News

Page 2 - Noah Berkowitz News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Noah Berkowitz. Real-time updates on events, politics, business and more.

Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission
United Kingdom United States Dennis Riedl Origar Beta Noah Berkowitz Bristol Myers Squibb

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (lusp

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...
United States Origar Beta Noah Berkowitz Bristol Myers Squibb Hematology Development Drug Administration

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia

Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc....
United States Nina Goworek Ali Taher Origar Beta Noah Berkowitz Bristol Myers Squibb

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...
Noah Berkowitz Bristol Myers Squibb Kimberly Whitefield Drug Administration Bristol Myers Squibb Company Exchange Commission

BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL

BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL. The trial met primary and key secondary endpoints, demonstrating a highly statistically significant impr...
Noah Berkowitz Bristol Myers Squibb Cell Therapy Development Myers Squibb நோவா பெர்கோவிட்ஸ் பிரிஸ்டல் மைஸ் ஸ்க்விப்ப்

Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission

If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontli...
United States United Kingdom Nina Goworek Noah Berkowitz Bristol Myers Squibb Hematology Development

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science